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Dysregulation of cholesterol homeostasis in the CNS has 
been associated with various neurodegenerative disorders, 
including Parkinson’s, Huntington’s, and Alzheimer’s dis-
ease (AD) (1). Evidence supporting this relationship de-
rives, for example, from recent genomic-wide association 
studies that have identified several loci involved in lipid 
metabolism among the AD-susceptible genes (2, 3). For ex-
ample, the 4 allele of the APOE gene encoding apoE is 
undoubtedly the most strong genetic risk factor, but re-
cently other genes have been identified such as BIN1, CLU, 
PICALM, ABCA7, ABCA1, ABCG1, and SORL1 (4).
However, the exact mechanisms linking cholesterol ho-
meostasis derangement and AD pathogenesis are far from 
being understood and conflicting data have been released, 
describing both increased, decreased, or no change of cho-
lesterol levels in different brain sections and the cerebro-
spinal fluid (CSF) of AD patients compared with control 
subjects (5).
Approximately 30% of the total body cholesterol is present 
in the brain, where it plays a crucial role in the synaptogen-
esis and maintenance of neuronal plasticity and function 
(6). The brain relies on endogenous local cholesterol syn-
thesis because it is isolated from other body compartments 
by the blood-brain barrier (7, 8). While cholesterol synthe-
sis in neurons and glial cells is very high during embryo-
genesis, adult neurons progressively lose this capacity and 
most exclusively rely on cholesterol produced from other 
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cells such as astrocytes (9, 10), which show at least 2- to 
3-fold higher cholesterol synthesis capacity compared with 
neurons (1).
Brain cholesterol is transported from astrocytes to neu-
rons by lipoproteins that have been identified in the human 
CSF, with a size and density similar to that of plasma HDL 
(11). These particles vary widely in size (13–20 nm), are 
mainly spherical, and contain apoE, apoA-I, apoJ, apoA-II, 
apoA-IV, and apoD (8, 11, 12). CSF HDL-like particles guar-
antee the transport of cholesterol from astrocytes to neu-
rons that is necessary for providing the proper amount of 
cholesterol and phospholipids for neurite formation and 
synaptogenesis (11). Cholesterol transport occurs thanks 
to the activity of specific membrane transporters such as 
ABCA1 and ABCG1 (13). ABCA1 mediates the secretion of 
nascent discoidal apoE-rich particles from astrocytes; these 
nascent lipoproteins undergo further cholesterol and 
phospholipid enrichment through the activity of ABCG1 
expressed both in astrocytes and neurons (14). This lipid 
enrichment, together with the activity of remodeling en-
zymes, such as the cholesterol esterifying enzyme lecithin 
cholesterol acyltransferase, leads to the conversion of na-
scent into mature particles that eventually deliver choles-
terol to neurons by interacting with specific apoE receptors, 
such as the LDL receptor and its family members (15).
Few published data suggest that CSF lipoprotein bio-
genesis, maturation, and cholesterol transport capacity 
might be altered in AD (16, 17). In particular, Yassine et al. 
(16) recently showed that CSF HDL-like particle capacity 
to promote cholesterol efflux through ABCA1 is impaired 
in both AD patients and subjects with mild cognitive im-
pairment, indicating a derangement of brain lipoprotein 
function in the early phases of the disease-associated 
neurodegeneration.
In the present work, we confirmed and extended the ob-
servation of Yassine et al. by evaluating the capacity of the 
CSF of AD patients and controls to promote cholesterol 
efflux; namely, cholesterol efflux capacity (CEC), by all 
major cholesterol efflux pathways of ABCA1 and ABCG1, 
two transporters largely expressed in the CNS (18), and the 
unmediated process of passive diffusion. We also evaluated 
whether the alteration of CSF-CEC may occur in degenera-
tive dementias (DEMs) other than AD. Finally, we looked 
at the potential relationship between CSF HDL-like parti-
cle CEC and the presence of the apoE4 isoform, as well as 




The study included a group of patients diagnosed with AD (n = 
37), a group of patients with non-AD DEM (n = 16), and a control 
group of patients with more than 20 heterogeneous conditions 
unrelated to DEM (controls; n = 39). CSF samples were obtained 
by lumbar puncture for routine clinical diagnosis after an in-
formed consent using a form approved by the local ethics com-
mittees. Specimens were immediately stored at 80°C and slowly 
defrosted in ice only at the moment of utilization. None of the 
samples presented alterations at the macroscopic examination. 
The study was conducted in accordance with the ethical princi-
ples set forth in the Declaration of Helsinki.
The control group included individuals with psychiatric disor-
ders, hydrocephalus, tumors, peripheral neuropathy, and those 
who underwent lumbar puncture for suspected demyelinating 
disorders discharged with no neurological diseases. The AD diag-
nosis was performed according to NINCDS-ADRDA (19) and sub-
sequent research criteria (20). In the non-AD DEM group, 
patients were diagnosed as non-AD DEM according to established 
clinical criteria (21–25) and included behavioral variants of fron-
totemporal DEM, amyotrophic lateral sclerosis-frontotemporal 
spectrum disorder, corticobasal syndrome, nonfluent primary 
progressive aphasia, semantic variant primary progressive aphasia, 
progressive supranuclear palsy, and Parkinson’s disease DEM.
Biochemical analyses
The CSF neurobiomarker profile [amyloid  (A) 1-42, total tau, 
and phosphorylated tau levels] was evaluated by ELISA (Fujirebio, 
Ghent, Belgium). Total apoE and apoE4 levels were measured in 
CSF by ELISA (MBL, Nagoya, Japan). The kit measures the amount 
of human total apoE and apoE4 specifically with high sensitivity 
using affinity-purified polyclonal antibody against total apoE and 
monoclonal antibody against apoE4. The minimum detectable 
concentration is 4 ng/ml and 8 ng/ml for total apoE and apoE4, 
respectively. Because apoE4 production is discrete and not con-
tinuous according to the null, heterozygous, or homozygous gen-
otype, the apoE4/total apoE ratio could be used to identify the 
apo4 genotype (26, 27). Based on this concept we stratified sub-
jects in apo4 carriers when the apoE4/apoE ratio was >0 (26, 28). 
CSF apoA-I was measured by ELISA (Abcam, Cambridge, UK). The 
minimum detectable apoA-I concentration of the kit is 59 pg/ml.
CEC
We evaluated CSF-CEC through the cholesterol transporters 
ABCA1 and ABCG1 that are expressed in CNS and involved in the 
cholesterol cross-talk between astrocytes and neurons (11). In ad-
dition, we also measured CEC through the passive diffusion pro-
cess, a spontaneous desorption phenomenon that does not 
require the expression of membrane transporters (29).
CSF was evaluated for its capacity to promote cholesterol efflux 
by slightly modifying a standard radioisotopic technique commonly 
used for the evaluation of serum HDL CEC and characterized by 
the utilization of specific cell models overexpressing the single cho-
lesterol transporters (30–32). In particular, we used J774 mouse 
macrophages in basal conditions to measure CEC by passive diffu-
sion; J774 cells treated with 0.3 mM cpt-cAMP (Sigma-Aldrich, St. 
Louis, MO), which upregulates the ABCA1 transporter (33), were 
used for total CEC; the specific ABCA1 CEC was then calculated 
as the difference in CEC between ABCA1-expressing J774 and 
J774 cells in basal conditions. ABCG1-mediated CEC was evalu-
ated in hABCG1-expressing Chinese hamster ovary (CHO)-K1 cells 
and calculated as the difference in CEC between hABCG1-ex-
pressing and parent CHO-K1 control cells (34).
J774 macrophages were grown in 10% FCS containing DMEM 
(Lonza, Verviers, Belgium) in the presence of 1% penicillin-strep-
tomycin (Thermo Fisher Scientific, Carlsbad, CA). CHO cells 
were cultured in 10% FCS containing Ham’s F-12 (Lonza) in the 
presence of antibiotics.
In all assays, cells were plated (density of 120,000 cells/well for 
J774 and 10,000 cells/well for CHO) and following 24 h were 
labeled with [1,2-3H]cholesterol (PerkinElmer, Milano, Italy) for 
24 h in the presence of an inhibitor of the cholesterol esterifying 
enzyme acyl-CoA:cholesterol acyltransferase (Sandoz 58035; 
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the free form. After labeling, cells underwent an equilibration time 
in medium containing 0.2% free fatty acid BSA (Sigma-Aldrich). 
During this time, J774 underwent ABCA1 upregulation with a 
cAMP analogue. Cells were then washed to remove any cell death 
and subsequently exposed to CSF from controls, AD, and non-AD 
DEM subjects for 4–24 h depending on the pathway evaluated. 
Prior to the utilization, we did not perform any sample fraction-
ation to separate the HDL-like particles from the lipid-containing 
nanoparticles that have also been identified in the CSF (35) be-
cause of their negligible contribution to cholesterol efflux (16). 
The concentration of CSF used as cholesterol acceptor was 30% 
(v/v) for both cell models. In the case of ABCA1 CEC, this was 
based on previous reports (16). In the case of ABCG1 CEC, we 
assessed the optimal concentration of CSF to be used though pre-
liminary dose-response experiments with a pool of control CSF. 
Like what was seen for ABCA1 CEC (16), incubation with increas-
ing concentrations of CSF resulted in a significant, dose-depen-
dent increase of ABCG1-mediated CEC (r2 = 0.962, P = 0.019; 
supplemental Fig. S1). CSF-CEC was expressed as a percentage of 
the radioactivity released into the medium over the total radioac-
tivity incorporated by cells. A parallel set of cells was incubated 
with medium alone to provide a background efflux that was sub-
tracted from CEC values of CSF samples. To verify the cAMP-
mediated induction of ABCA1 expression, reference normal 
lipid-free human apoA-I (Sigma-Aldrich) was used in each experi-
ment. Similarly, as a control for ABCG1 CEC cell responsiveness, 
in each experiment we evaluated cholesterol efflux to native 
plasma HDL isolated from healthy donors by ultracentrifugation 
(36). In addition, a pool of normal human sera, as a reference 
standard, was tested in each assay and its CEC value was used to 
normalize the patients’ CSF-CEC values obtained in different ex-
periments to correct for the interassay variability.
Statistical analyses
Statistical analyses were performed using GraphPad Prism ver-
sion 6.0 (GraphPad Software Inc., La Jolla, CA). Every CSF sample 
was run in triplicate and average values and SDs were calculated 
for each percentage of efflux obtained. The D’Agostino and Pear-
son omnibus normality test was used to verify whether parameters 
were normally distributed. Normally distributed parameters were 
presented as means ± SDs, and skewed continuous parameters 
were expressed as medians (interquartile ranges). The compari-
son between the three groups of subjects was performed by one-
way ANOVA or the Kruskal-Wallis test for data normally and not 
normally distributed, respectively. In both cases, we corrected the 
results for multiple comparison by Dunn’s post hoc test. Categori-
cal variables were compared with the Chi-square test. The rela-
tionship between parameters was assessed by linear correlation 
analysis and the correlation coefficients (Spearman r was re-
ported). Statistical significance was defined as P < 0.05.
RESULTS
Demographic and clinical parameters
The demographic data and clinical parameters available 
for the cohort of the analyzed subjects are shown in Table 1. 
AD patients were significantly older compared with con-
trols (+15%), while the sex distribution was similar among 
groups. The AD group presented the typical neurobio-
marker CSF profile, characterized by a marked reduction 
of A 1-42 levels combined with a significant increase of 
total and phosphorylated tau. Conversely, both the con-
trols and the non-AD DEM groups displayed a non-
pathological neurobiochemical profile. As expected, the 
frequency of the apo4 genotype was markedly higher 
in AD patients.
CSF-CEC
We evaluated the capacity of CSF to promote cell choles-
terol efflux though the membrane transporter ABCA1. 
The actual ABCA1 expression in cells was demonstrated by 
the internal quality control obtained by cholesterol efflux 
induction with apoA-I and normal human serum (mean ± 
SD effluxes are shown in supplemental Table S1). CSF 
from AD patients displayed a lower ABCA1-mediated CEC 
compared with controls (73%; P = 0.001; Fig. 1). Con-
versely, non-AD DEM ABCA1-mediated CEC did not sig-
nificantly differ from that of controls (P > 0.999). To rule 
out the possibility that the difference between the control 
and AD groups was driven by the highest nine CEC values 
in the control group, we excluded them from the analysis 
and confirmed the significant, although attenuated, differ-
ence between the two groups (mean ± SD 0.39 ± 0.05% in 
controls compared with 0.21 ± 0.036% in AD; P = 0.048).
We also measured the capacity of CSF to promote cell 
cholesterol efflux through the membrane transporter 
ABCG1. The actual ABCG1 expression in cells was demon-
strated by the internal quality control obtained by choles-
terol efflux induction with isolated normal human HDL 
and normal human serum (supplemental Table S1). The 
TABLE 1. Demographic data and diagnostic parameters of studied subjects
Controls (n = 39) AD (n = 37) non-AD DEM (n = 16) P
Age (years) 60 ± 16 69 ± 9a 63 ± 8 aP < 0.01 vs. controls
Males [n (%)] 20 (51) 19 (49) 8 (50) 0.960
A 1-42 (ng/l) 966 (782–1,390) 472 (381–562)a 742 (555–1,414) aP < 0.0001 vs. controls and 
non-AD DEM
Total tau (ng/l) 120 (98–181) 607 (297–978)a,b 216 (103–549) aP < 0.0001 vs. controls
bP = 0.004 vs. non-AD DEM
Phosphorylated tau (ng/l) 30 (26–38) 84 (62–104)a 34 (16–50) aP < 0.0001 vs. controls and 
non-AD DEM
apoE4 carriers [n (%)] 7 (18) 26 (70)a 5 (31) aP < 0.0001 vs. controls and 
non-AD DEM
Normally distributed parameters are presented as means ± SDs, and skewed continuous parameters are 
expressed as medians (interquartile ranges). Statistically different values are reported in bold. CSF neurobiomarker 
(A 1-42, total tau, and phosphorylated tau) values were available for 12/39 subjects in the control group and 13/16 
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measurement of CSF ABCG1-mediated CEC showed that, 
like what was observed for ABCA1 CEC, values relative to 
AD patients were significantly lower than those of controls 
(33%; P = 0.004; Fig. 2). The reduction appeared to be 
specific for AD, as CSF from patients with non-AD DEM 
displayed CEC values comparable to those of the control 
group (P > 0.999).
Finally, by evaluating CFS-CEC mediated by the passive 
diffusion process, we found no differences between AD 
and control groups, while non-AD DEM patients displayed 
significantly lower values compared with control subjects 
(40%; P = 0.002; Fig. 3).
Measurement of apoE and apoA-I CSF levels
The measurement of apoE levels in the CSF of the three 
analyzed groups showed no difference comparing AD to 
controls (Fig. 4A). However, non-AD DEM values were 
slightly but significantly lower than those relative to the 
control group (P = 0.049). The quantification of CSF apoA-I 
did not reveal significant differences between groups 
(Fig. 4B).
CSF-CEC by apoE4 status
Stratifying all subjects of the study based on the absence 
or presence of the apoE4 isoform, we did not observe signifi-
cant differences in any of the CSF-CEC pathways (Table 2).
Correlations
Finally, we evaluated whether some correlations exist 
between the CSF-CEC mediated by each pathway analyzed 
and age, apolipoproteins levels, and neurobiomarkers of AD 
diagnosis. Results of linear-regression analyses considering 
all subjects together are reported in Table 3. None of the 
efflux pathways correlated with age. ABCG1 CEC was posi-
tively associated with CSF apoE levels. However, by analyz-
ing the three study groups separately, a significant positive 
correlation was conserved only in the control group (r = 
0.358, P = 0.027). A similar behavior was observed for the 
correlation between apoA-I and passive diffusion, signifi-
cant in the whole series of subjects but driven only by the 
control group (r = 0.413, P = 0.021).
None of the CSF-CEC pathways correlated with apoE4 
CSF levels. ABCG1 CSF-CEC correlated positively with A 
1-42, while ABCA1 CSF-CEC inversely correlated with both 
total and phosphorylated tau levels. All of these correla-
tions were absent analyzing the three groups separately 
(data not shown). The neurobiomarkers A 1-42, total tau, 
and phosphorylated tau did not correlate with age, neither 
considering all subjects together nor the three groups sep-
arately (data not shown).
DISCUSSION
Disturbances in brain cholesterol homeostasis, includ-
ing total content, trafficking between cells, and intracellu-
lar metabolism, are involved in AD pathogenesis (1). 
Considering brain cholesterol trafficking, the integrity of 
cholesterol fluxes between brain cells relies both on a nor-
mal membrane expression of cholesterol transporters/
receptors on the cell side and on a proper functionality of 
Fig. 1. CSF ABCA1-mediated CEC in control subjects, AD patients, 
and non-AD DEM patients. Each point of the scatter plot represents 
the mean of a triplicate analysis of each CSF sample. The plot reports 
the mean ± SD within each group. ABCA1 CEC was performed on 
29/39 CSF samples from AD patients.
Fig. 2. CSF ABCG1 CEC in control subjects, AD patients, and 
non-AD DEM patients. Each point of the scatter plot represents the 
mean of a triplicate analysis of each CSF sample. The plot reports 
the mean ± SD within each group.
Fig. 3. CSF passive diffusion CEC in control subjects, AD patients, 
and non-AD DEM patients. Each point of the scatter plot represents 
the mean of a triplicate analysis of each CSF sample. The plot reports 
the mean ± SD within each group. Passive diffusion CEC was per-
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HDL-like particles on the CSF side. In AD, alterations of 
genes coding for the membrane cholesterol transporters 
ABCA1 or ABCG1 and loss-of-function ABCA1 variants are 
risk factors for disease onset (4, 37, 38). We evaluated the 
brain cholesterol trafficking studying the function of CSF 
HDL-like particles in AD and non-AD DEM by testing CSF-
CEC on standardized cellular models expressing ABCA1 or 
ABCG1 transporters and analyzing its relationship with 
other AD-related laboratory parameters.
Our results not only confirm the previously reported re-
duction of CSF ABCA1-mediated CEC (16) but also de-
scribe an impairment of ABCG1-mediated CEC specifically 
occurring in AD.
Overall, the results of our study support the existence of 
a pathophysiological link between the impairment of brain 
cholesterol fluxes mediated by CSF HDL-like particles and 
AD. The dysfunction of CSF HDL-like particles in promot-
ing ABCA1- and ABCG1-mediated cholesterol efflux may 
have deleterious consequences on neurons. In fact, these 
cells, unable to synthetize all cholesterol they need (1), rely 
on cholesterol uptake from CSF HDL particles, which, in 
turn, enrich in cholesterol through the interaction with 
the astrocyte membrane cholesterol transporters ABCA1 
and ABCG1 (13). Thus, a defect in CEC of CSF HDL-like 
particles may end up in lower supply of cholesterol to neu-
rons, leading to their apoptosis and eventually to neurode-
generation (39). As ABCA1 and ABCG1 are also expressed 
by neurons, one could argue that reduced CSF-CEC might 
also end up in less cholesterol removal from these cells. 
However, as the requirement of neurons for cholesterol 
is very high and satisfied only by a continuous supply 
from astrocytes, it is likely that the net effect of CSF-CEC 
impairment is that of neuron cholesterol depletion. This 
effect is even more important considering the increase 
in PCSK9 CSF levels in AD, which has been recently re-
ported by us and by others (26, 40). PCSK9, in fact, re-
duces neuronal expression of receptors for cholesterol 
uptake (41, 42). Thus, increased PCSK9 CSF levels and 
reduced CSF-CEC may concur in neuronal cholesterol 
depletion and neurodegeneration.
Our finding of a multiple pathway impairment of CSF-
CEC only in AD patients points to a role of CSF HDL-like 
particles dysfunction specifically in AD neuronal damage. 
The theoretical role of CSF lipid nanoparticles and albu-
min in cell cholesterol efflux promotion is in fact extremely 
unlikely, as indicated by previous studies on their concen-
tration in the brain and cholesterol efflux ability (16, 43). 
In AD, HDL-like particle dysfunction might be due to the 
interference on lipoprotein-mediated brain cholesterol 
trafficking by A metabolism and the formation of neuro-
fibrillary tangles, as discussed below.
CSF-CEC likely depends not only on CSF HDL-like par-
ticle concentration but also on their size and composition, 
as widely demonstrated for serum HDL (44). CSF content 
in apoE, produced in CNS (45) and in apoA-I, which de-
rives from the peripheral circulation through a cholesterol-
dependent process (46, 47), reflects HDL-like particle 
concentration and was comparable among groups. More-
over, we did not find any correlation between CEC and CSF 
apolipoprotein levels in AD, while ABCG1 CEC and passive 
diffusion correlated with apoE and apoA-I only in the con-
trol group, respectively.
The similarity of apoE and apoA-I levels in controls 
and AD that we found is in line with the results of some 
previous studies (48–50) but not with others (16, 48, 50), 
making necessary further investigation to clarify this 
aspect.
From our data we may speculate that modifications of 
CSF-CEC in AD appear to be related to changes in HDL-
like particle quality and function rather than concentra-
tion. Concerning the difference between the control and 
AD groups, impaired phospholipid or triglyceride enrich-
ment of HDL-like particles might derive from the reduced 
CSF lecithin cholesterol acyltransferase activity reported in 
AD patients (17) and be associated with a specific impair-
ment of the subclass of larger particles, representing the 
major lipoprotein fraction in the cerebrospinal fluid (12, 
51), with consequent altered affinity for the ABCG1 trans-
porter (52, 53). Our data showing in the control group low 
values of ABCA1 CEC compared with those of ABCG1 CEC 
are consistent with the notion that in human CSF mainly 
large and spherical particles are present (11, 12). An alter-
native explanation for ABCG1 CEC impairment in AD is 
the altered A protein cargo previously described in AD 
CSF particles (54) and specifically on the large HDL1 sub-
fraction (54, 55). This hypothesis is somehow consistent 
with the relationship that we previously observed between 
an increased HDL content of serum amyloid A, another 
misfolded protein involved in the acute-phase response, 
Fig. 4. CSF levels (µg/ml) of (A) apoE and (B) 
apoA-I in control subjects, AD patients, and non-AD 
DEM patients. Each point of the scatter plot represents 
the mean of a duplicate analysis of each CSF sample. 
The plot reports the mean ± SD within each group. 
ApoE levels were evaluated in 35/39 CSF samples 
from AD patients. apoA-I levels were evaluated in 30/39 
CSF samples from control subjects, 35/37 samples 
from AD patients, and 13/16 samples from non-AD 
DEM patients.
TABLE 2. CSF cholesterol efflux values stratified between carriers 
and noncarriers of the apoE4 isoform
apoE4 carriers apoE4 noncarriers
% P
ABCG1 CEC 2.27 ± 1.24 2.39 ± 1.41 0.969
ABCA1 CEC 0.60 ± 0.70 0.43 ± 0.52 0.162
Passive diffusion CEC 0.82 ± 0.36 1.03 ± 0.60 0.090
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and a reduced capacity of serum HDL to promote ABCG1-
mediated cholesterol efflux (31).
The mentioned specificity of CSF-CEC alterations in AD 
and the differences with other types of DEM are further 
underlined by our finding that only non-AD subjects pre-
sented a reduction in CSF-CEC mediated by passive diffu-
sion. This finding is likely explained by the lower CSF apoE 
levels of these patients, as cell passive diffusion is a process 
known to be driven by relative gradients of cholesterol and 
extracellular acceptors (56). The reduced concentration of 
apoE observed in non-AD DEM are consistent with previ-
ous findings (50, 57).
Our data suggest also that the impairment of CSF-CEC 
in AD is independent of the presence of the apoE4 iso-
form, one of the major genetic risk factors for AD (4). Our 
results are in line with Yassine et al. (16), who also did not 
find significant correlations between CSF ABCA1-mediated 
CEC and the apo genotype. In addition, our data are also 
consistent with previous work performed with isolated 
apoE4 or apoE4-containing synthetic HDL on ABCA1- and 
ABCG1-mediated efflux (58, 59). However, also taking into 
account other previous data on the reduced capacity of the 
isolated human apoE4 isoform to promote neuron choles-
terol efflux (60, 61), a further confirmation of CSF-CEC 
independence to the apo4 genotype in a larger popula-
tion is needed.
The correlations that we found between CSF-CEC and 
the neurochemical biomarkers used for AD diagnosis are 
suggestive of a mechanistic link between HDL-like particle 
quality and biochemical abnormalities involved in A pep-
tide deposition and protein tau phosphorylation. This as-
sociation seems to be independent of age because age did 
not correlate with either CSF-CEC or with the AD biomark-
ers. In detail, the ABCG1 CSF-CEC was directly associated 
with A levels, which decrease with A deposition in the 
insoluble form, and ABCA1 CEC was inversely correlated 
to phosphorylated tau levels. Given that no cause-and-
effect relationship can be inferred, it is intriguing consider-
ing, for example, that neuronal cholesterol content and 
distribution have been involved in A metabolism, with 
cholesterol depletion reducing A solubility (62, 63).
On the other hand, tau is present in lipid rafts, which 
are specialized cholesterol- and receptor-rich membrane 
domains (64). Membrane raft disruption in neurons 
caused by cholesterol depletion has been shown to cause 
perturbations of membrane raft-associated cytoskeleton 
proteins, including tau (65). In addition, reduced raft 
cholesterol has been found to promote tau hyperphos-
phorylation in Niemann-Pick C1-deficient cells (66). 
Thus, impaired CSF HDL-like particle-mediated brain 
cholesterol trafficking might be somehow involved in the 
complex and mostly yet ununderstood processes leading 
to the formation of amyloid plaques and neurofibrillary 
tangles in AD.
The main limitations are relative to the descriptive na-
ture of the work and to the fact that our cell models are 
different from the cerebral cells with which the CSF is in 
contact, except for the expression of the cholesterol trans-
porter. For these reasons, our findings need to be inte-
grated with future studies to obtain mechanistic insights.
Another limitation concerns the small sample size, espe-
cially for the non-AD DEM group. For example, the small 
numbers may not be sufficiently statistically powered to de-
tect differences in the stratification of CSF-CEC based on 
the genotype or in correlation studies within groups. In 
particular, the small sample size has conditioned the im-
possibility to make stratified analyses on control patients, 
presenting a wide distribution of CEC values. The particu-
lar nature of CSF makes obviously difficult obtaining sam-
ples from healthy subjects but renders also difficult 
assembling a homogeneous control group. However, we 
were able to confirm the presence of a reduced but still 
statistically significant difference in CEC values between 
AD and controls after excluding from the analyses those 
control samples giving the highest ABCA1-CEC values. On 
the other hand, no particular diagnosis was associated with 
the highest ABCA1-CEC values and, most importantly, the 
high heterogeneity of diagnoses in our control group re-
duced the possibility of specific bias. A further limitation of 
our study derives from the limited CSF sample volume, 
which did not allow us to study physicochemical character-
istics of CSF HDL-like particles.
CONCLUSION
We demonstrated that CSF capacity to promote cell cho-
lesterol efflux via the active transporters ABCA1 and 
ABCG1 is specifically impaired in AD, possibly due to quali-
tative modifications in CSF HDL-like particles. Such im-
pairment correlates with the main neurobiochemical 
markers of AD, A, and p-tau, suggesting the existence of 
pathophysiological links between reduced neuronal cho-
lesterol supply and neurodegeneration in AD. Our data, 
together with further information worth obtaining on the 
precise mechanisms of CSF HDL-like particle dysfunction, 
may open the way to developing new lipoprotein-based 
pharmacological approaches, such as modulators of HDL-
like particle maturation, to ameliorate brain cholesterol 
trafficking in AD.
TABLE 3. Correlations
ABCG1 CEC ABCA1 CEC
Passive diffusion 
CEC
Age r = 0.078 r = 0.102 r = 0.123
P = 0.463 P = 0.358 P = 0.268
apoE r = 0.370 r = 0.011 r = 0.170
P < 0.001 P = 0.920 P = 0.132
apoE4 r = 0.046 r = 0.153 r = 0.174
P = 0.675 P = 0.176 P = 0.121
apoA-I r = 0.048 r = 0.061 r = 0.354
P = 0.692 P = 0.626 P = 0.003
A 1-42 r = 0.305 r = 0.203 r = 0.068
P = 0.025 P = 0.172 P = 0.647
Total tau r = 0.212 r = 0.348 r = 0.092
P = 0.127 P = 0.018 P = 0.542
Phosphorylated tau r = 0.225 r = 0.294 r = 0.269
P = 0.106 P = 0.048 P = 0.070
The relationship between parameters was established by correlation 
analysis, and the Spearman coefficients are reported. Significant 
















Supplemental Material can be found at:
CSF function in Alzheimer’s disease 1455
REFERENCES
 1. Arenas, F., C. Garcia-Ruiz, and J. C. Fernandez-Checa. 2017. 
Intracellular cholesterol trafficking and impact in neurodegenera-
tion. Front. Mol. Neurosci. 10: 382.
 2. Dong, H. K., J. A. Gim, S. H. Yeo, and H. S. Kim. 2017. Integrated 
late onset Alzheimer’s disease (LOAD) susceptibility genes: choles-
terol metabolism and trafficking perspectives. Gene. 597: 10–16.
 3. Lambert, J. C., C. A. Ibrahim-Verbaas, D. Harold, A. C. Naj, R. 
Sims, C. Bellenguez, A. L. DeStafano, J. C. Bis, G. W. Beecham, B. 
Grenier-Boley, et al. 2013. Meta-analysis of 74,046 individuals identi-
fies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45: 
1452–1458.
 4. Picard, C., C. Julien, J. Frappier, J. Miron, L. Theroux, D. Dea, 
United Kingdom Brain Expression Consortium and for the 
Alzheimer’s Disease Neuroimaging Initiative, J. C. S. Breitner, and 
J. Poirier. 2018. Alterations in cholesterol metabolism-related genes 
in sporadic Alzheimer’s disease. Neurobiol. Aging. 66: 180.e181–180.
e189.
 5. Wood, W. G., L. Li, W. E. Muller, and G. P. Eckert. 2014. Cholesterol 
as a causative factor in Alzheimer’s disease: a debatable hypothesis. 
J. Neurochem. 129: 559–572.
 6. Dietschy, J. M., and S. D. Turley. 2004. Thematic review series: brain 
lipids. Cholesterol metabolism in the central nervous system dur-
ing early development and in the mature animal. J. Lipid Res. 45: 
1375–1397.
 7. Dietschy, J. M. 2009. Central nervous system: cholesterol turn-
over, brain development and neurodegeneration. Biol. Chem. 390: 
287–293.
 8. Chang, T. Y., Y. Yamauchi, M. T. Hasan, and C. Chang. 2017. 
Cellular cholesterol homeostasis and Alzheimer’s disease. J. Lipid 
Res. 58: 2239–2254.
 9. Quan, G., C. Xie, J. M. Dietschy, and S. D. Turley. 2003. Ontogenesis 
and regulation of cholesterol metabolism in the central nervous sys-
tem of the mouse. Brain Res. Dev. Brain Res. 146: 87–98.
 10. Ikonen, E. 2008. Cellular cholesterol trafficking and compartmen-
talization. Nat. Rev. Mol. Cell Biol. 9: 125–138.
 11. Vitali, C., C. L. Wellington, and L. Calabresi. 2014. HDL and choles-
terol handling in the brain. Cardiovasc. Res. 103: 405–413.
 12. Koch, S., N. Donarski, K. Goetze, M. Kreckel, H. J. Stuerenburg, 
C. Buhmann, and U. Beisiegel. 2001. Characterization of four li-
poprotein classes in human cerebrospinal fluid. J. Lipid Res. 42: 
1143–1151.
 13. Chen, J., X. Zhang, H. Kusumo, L. G. Costa, and M. Guizzetti. 
2013. Cholesterol efflux is differentially regulated in neurons and 
astrocytes: implications for brain cholesterol homeostasis. Biochim. 
Biophys. Acta. 1831: 263–275.
 14. Tarr, P. T., and P. A. Edwards. 2008. ABCG1 and ABCG4 are coex-
pressed in neurons and astrocytes of the CNS and regulate choles-
terol homeostasis through SREBP-2. J. Lipid Res. 49: 169–182.
 15. Wang, H., and R. H. Eckel. 2014. What are lipoproteins doing in the 
brain? Trends Endocrinol. Metab. 25: 8–14.
 16. Yassine, H. N., Q. Feng, J. Chiang, L. M. Petrosspour, A. N. Fonteh, 
H. C. Chui, and M. G. Harrington. 2016. ABCA1-mediated choles-
terol efflux capacity to cerebrospinal fluid is reduced in patients 
with mild cognitive impairment and Alzheimer’s disease. J. Am. 
Heart Assoc. 5: e002886.
 17. Demeester, N., G. Castro, C. Desrumaux, C. De Geitere, J. C. 
Fruchart, P. Santens, E. Mulleners, S. Engelborghs, P. P. De Deyn, J. 
Vandekerckhove, et al. 2000. Characterization and functional stud-
ies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol 
acyltransferase in CSF of normal individuals and patients with 
Alzheimer’s disease. J. Lipid Res. 41: 963–974.
 18. Vance, J. E., and H. Hayashi. 2010. Formation and function of apoli-
poprotein E-containing lipoproteins in the nervous system. Biochim. 
Biophys. Acta. 1801: 806–818.
 19. Dubois, B., H. H. Feldman, C. Jacova, S. T. Dekosky, P. Barberger-
Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, 
et al. 2007. Research criteria for the diagnosis of Alzheimer’s disease: 
revising the NINCDS-ADRDA criteria. Lancet Neurol. 6: 734–746.
 20. Dubois, B., H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo, 
K. Blennow, S. T. DeKosky, S. Gauthier, D. Selkoe, R. Bateman, 
et al. 2014. Advancing research diagnostic criteria for Alzheimer’s 
disease: the IWG-2 criteria. Lancet Neurol. 13: 614–629.
 21. Armstrong, M. J., I. Litvan, A. E. Lang, T. H. Bak, K. P. Bhatia, B. 
Borroni, A. L. Boxer, D. W. Dickson, M. Grossman, M. Hallett, 
et al. 2013. Criteria for the diagnosis of corticobasal degeneration. 
Neurology. 80: 496–503.
 22. Gorno-Tempini, M. L., A. E. Hillis, S. Weintraub, A. Kertesz, M. 
Mendez, S. F. Cappa, J. M. Ogar, J. D. Rohrer, S. Black, B. F. Boeve, 
et al. 2011. Classification of primary progressive aphasia and its vari-
ants. Neurology. 76: 1006–1014.
 23. Litvan, I., Y. Agid, J. Jankovic, C. Goetz, J. P. Brandel, E. C. Lai, 
G. Wenning, L. D’Olhaberriague, M. Verny, K. R. Chaudhuri, et 
al. 1996. Accuracy of clinical criteria for the diagnosis of progres-
sive supranuclear palsy (Steele-Richardson-Olszewski syndrome). 
Neurology. 46: 922–930.
 24. Rascovsky, K., J. R. Hodges, D. Knopman, M. F. Mendez, J. H. 
Kramer, J. Neuhaus, J. C. van Swieten, H. Seelaar, E. G. Dopper, 
C. U. Onyike, et al. 2011. Sensitivity of revised diagnostic criteria 
for the behavioural variant of frontotemporal dementia. Brain. 134: 
2456–2477.
 25. Strong, M. J., S. Abrahams, L. H. Goldstein, S. Woolley, P. 
McLaughlin, J. Snowden, E. Mioshi, A. Roberts-South, M. Benatar, 
T. Hortobágyi, et al. 2017. Amyotrophic lateral sclerosis - frontotem-
poral spectrum disorder (ALS-FTSD): revised diagnostic criteria. 
Amyotroph. Lateral Scler. Frontotemporal Degener. 18: 153–174.
 26. Zimetti, F., P. Caffarra, N. Ronda, E. Favari, M. P. Adorni, I. Zanotti, 
F. Bernini, F. Barocco, M. Spallazzi, D. Galimberti, et al. 2017. 
Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s 
disease. J. Alzheimers Dis. 55: 315–320.
 27. Calero, O., L. Garcia-Albert, A. Rodriguez-Martin, S. Veiga, and M. 
Calero. 2018. A fast and cost-effective method for apolipoprotein E 
isotyping as an alternative to APOE genotyping for patient screen-
ing and stratification. Sci. Rep. 8: 5969.
 28. Fukumoto, H., M. Ingelsson, N. Garevik, L. O. Wahlund, N. Nukina, 
Y. Yaguchi, M. Shibata, B. T. Hyman, G. W. Rebeck, and M. C. 
Irizarry. 2003. APOE epsilon 3/epsilon 4 heterozygotes have an el-
evated proportion of apolipoprotein E4 in cerebrospinal fluid rela-
tive to plasma, independent of Alzheimer’s disease diagnosis. Exp. 
Neurol. 183: 249–253.
 29. Favari, E., A. Chroni, U. J. Tietge, I. Zanotti, J. C. Escola-Gil, and F. 
Bernini. 2015. Cholesterol efflux and reverse cholesterol transport. 
Handb. Exp. Pharmacol. 224: 181–206.
 30. Adorni, M. P., N. Ferri, S. Marchiano, V. Trimarco, F. Rozza, R. Izzo, 
F. Bernini, and F. Zimetti. 2017. Effect of a novel nutraceutical com-
bination on serum lipoprotein functional profile and circulating 
PCSK9. Ther. Clin. Risk Manag. 13: 1555–1562.
 31. Zimetti, F., S. De Vuono, M. Gomaraschi, M. P. Adorni, E. Favari, 
N. Ronda, M. A. Ricci, F. Veglia, L. Calabresi, and G. Lupattelli. 
2017. Plasma cholesterol homeostasis, HDL remodeling and func-
tion during the acute phase reaction. J. Lipid Res. 58: 2051–2060.
 32. Vigna, G. B., E. Satta, F. Bernini, S. Boarini, C. Bosi, L. Giusto, E. 
Pinotti, P. Tarugi, A. Vanini, S. Volpato, et al. 2014. Flow-mediated 
dilation, carotid wall thickness and HDL function in subjects 
with hyperalphalipoproteinemia. Nutr. Metab. Cardiovasc. Dis. 24: 
777–783.
 33. Favari, E., F. Zimetti, A. E. Bortnick, M. P. Adorni, I. Zanotti, M. 
Canavesi, and F. Bernini. 2005. Impaired ATP-binding cassette 
transporter A1-mediated sterol efflux from oxidized LDL-loaded 
macrophages. FEBS Lett. 579: 6537–6542.
 34. Greco, D., D. Kocyigit, M. P. Adorni, C. Marchi, N. Ronda, F. 
Bernini, K. M. Gurses, H. Canpinar, D. Guc, S. H. Oguz, et al. 2018. 
Vitamin D replacement ameliorates serum lipoprotein functions, 
adipokine profile and subclinical atherosclerosis in pre-menopausal 
women. Nutr. Metab. Cardiovasc. Dis. 28: 822–829.
 35. Harrington, M. G., A. N. Fonteh, E. Oborina, P. Liao, R. P. Cowan, 
G. McComb, J. N. Chavez, J. Rush, R. G. Biringer, and A. F. Huhmer. 
2009. The morphology and biochemistry of nanostructures provide 
evidence for synthesis and signaling functions in human cerebrospi-
nal fluid. Cerebrospinal Fluid Res. 6: 10.
 36. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution 
and chemical composition of ultracentrifugally separated lipopro-
teins in human serum. J. Clin. Invest. 34: 1345–1353.
 37. Beecham, G. W., K. Hamilton, A. C. Naj, E. R. Martin, M. 
Huentelman, A. J. Myers, J. J. Corneveaux, J. Hardy, J. P. Vonsattel, 
S. G. Younkin, et al. 2014. Genome-wide association meta-analysis 
of neuropathologic features of Alzheimer’s disease and related de-
mentias. PLoS Genet. 10: e1004606.
 38. Nordestgaard, L. T., A. Tybjaerg-Hansen, B. G. Nordestgaard, and 
R. Frikke-Schmidt. 2015. Loss-of-function mutation in ABCA1 and 

















Supplemental Material can be found at:
1456 Journal of Lipid Research Volume 60, 2019
 39. Koudinov, A. R., and N. V. Koudinova. 2005. Cholesterol homeosta-
sis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 
229–230: 233–240.
 40. Courtemanche, H., E. Bigot, M. Pichelin, B. Guyomarch, C. 
Boutoleau-Bretonniere, C. Le May, P. Derkinderen, and B. Cariou. 
2018. PCSK9 concentrations in cerebrospinal fluid are not specifi-
cally increased in Alzheimer’s disease. J. Alzheimers Dis. 62: 1519–1525.
 41. Kysenius, K., P. Muggalla, K. Matlik, U. Arumae, and H. J. Huttunen. 
2012. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 lev-
els and signaling. Cell. Mol. Life Sci. 69: 1903–1916.
 42. Poirier, S., G. Mayer, S. Benjannet, E. Bergeron, J. Marcinkiewicz, 
N. Nassoury, H. Mayer, J. Nimpf, A. Prat, and N. G. Seidah. 2008. 
The proprotein convertase PCSK9 induces the degradation of low 
density lipoprotein receptor (LDLR) and its closest family members 
VLDLR and ApoER2. J. Biol. Chem. 283: 2363–2372.
 43. Li, X. M., W. H. Tang, M. K. Mosior, Y. Huang, Y. Wu, W. Matter, V. 
Gao, D. Schmitt, J. A. Didonato, E. A. Fisher, et al. 2013. Paradoxical 
association of enhanced cholesterol efflux with increased incident 
cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33: 1696–1705.
 44. Rothblat, G. H., and M. C. Phillips. 2010. High-density lipoprotein 
heterogeneity and function in reverse cholesterol transport. Curr. 
Opin. Lipidol. 21: 229–238.
 45. Liao, F., H. Yoon, and J. Kim. 2017. Apolipoprotein E metabolism 
and functions in brain and its role in Alzheimer’s disease. Curr. 
Opin. Lipidol. 28: 60–67.
 46. Chiesa, G., C. Parolini, M. Canavesi, N. Colombo, C. R. Sirtori, R. 
Fumagalli, G. Franceschini, and F. Bernini. 1998. Human apolipo-
proteins A-I and A-II in cell cholesterol efflux: studies with trans-
genic mice. Arterioscler. Thromb. Vasc. Biol. 18: 1417–1423.
 47. Zhou, A. L., S. K. Swaminathan, G. L. Curran, J. F. Poduslo, V. J. 
Lowe, L. Li, and K. K. Kandimalla. 2019. Apolipoprotein A-I crosses 
the blood-brain barrier through clathrin-independent and choles-
terol-mediated endocytosis. J. Pharmacol. Exp. Ther. 369: 481–488.
 48. Talwar, P., J. Sinha, S. Grover, R. Agarwal, S. Kushwaha, M. V. 
Srivastava, and R. Kukreti. 2016. Meta-analysis of apolipoprotein E 
levels in the cerebrospinal fluid of patients with Alzheimer’s disease. 
J. Neurol. Sci. 360: 179–187.
 49. Song, H., K. Saito, M. Seishima, A. Noma, K. Urakami, and K. 
Nakashima. 1997. Cerebrospinal fluid apo E and apo A-I concentrations 
in early- and late-onset Alzheimer’s disease. Neurosci. Lett. 231: 175–178.
 50. Johansson, P., E. G. Almqvist, M. Bjerke, A. Wallin, J. O. Johansson, 
U. Andreasson, K. Blennow, H. Zetterberg, and J. Svensson. 2017. 
Reduced cerebrospinal fluid concentration of apolipoprotein A-I in 
patients with Alzheimer’s disease. J. Alzheimers Dis. 59: 1017–1026.
 51. Kontush, A. 2004. Apolipoprotein Abeta: black sheep in a good fam-
ily. Brain Pathol. 14: 433–447.
 52. Gelissen, I. C., M. Harris, K. A. Rye, C. Quinn, A. J. Brown, M. 
Kockx, S. Cartland, M. Packianathan, L. Kritharides, and W. Jessup. 
2006. ABCA1 and ABCG1 synergize to mediate cholesterol export 
to apoA-I. Arterioscler. Thromb. Vasc. Biol. 26: 534–540.
 53. Sankaranarayanan, S., J. F. Oram, B. F. Asztalos, A. M. Vaughan, 
S. Lund-Katz, M. P. Adorni, M. C. Phillips, and G. H. Rothblat. 
2009. Effects of acceptor composition and mechanism of ABCG1-
mediated cellular free cholesterol efflux. J. Lipid Res. 50: 275–284.
 54. Koudinov, A. R., T. T. Berezov, and N. V. Koudinova. 2001. The 
levels of soluble amyloid beta in different high density lipoprotein 
subfractions distinguish Alzheimer’s and normal aging cerebrospinal 
fluid: implication for brain cholesterol pathology? Neurosci. Lett. 
314: 115–118.
 55. Guyton, J. R., S. E. Miller, M. E. Martin, W. A. Khan, A. D. Roses, and 
W. J. Strittmatter. 1998. Novel large apolipoprotein E-containing 
lipoproteins of density 1.006–1.060 g/ml in human cerebrospinal 
fluid. J. Neurochem. 70: 1235–1240.
 56. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. 
C. Phillips, and G. H. Rothblat. 2007. The roles of different path-
ways in the release of cholesterol from macrophages. J. Lipid Res. 48: 
2453–2462.
 57. Landén, M., C. Hesse, P. Fredman, B. Regland, A. Wallin, and K. 
Blennow. 1996. Apolipoprotein E in cerebrospinal fluid from pa-
tients with Alzheimer’s disease and other forms of dementia is re-
duced but without any correlation to the apoE4 isoform. Dementia. 
7: 273–278.
 58. Dafnis, I., C. Raftopoulou, C. Mountaki, E. Megalou, V. I. Zannis, 
and A. Chroni. 2018. ApoE isoforms and carboxyl-terminal- 
truncated apoE4 forms affect neuronal BACE1 levels and Abeta 
production independently of their cholesterol efflux capacity. 
Biochem. J. 475: 1839–1859.
 59. Kim, W. S., A. S. Rahmanto, A. Kamili, K. A. Rye, G. J. Guillemin, 
I. C. Gelissen, W. Jessup, A. F. Hill, and B. Garner. 2007. Role of 
ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux 
to apolipoprotein E discs and suppression of amyloid-beta peptide 
generation. J. Biol. Chem. 282: 2851–2861.
 60. Minagawa, H., J. S. Gong, C. G. Jung, A. Watanabe, S. Lund-Katz, M. 
C. Phillips, H. Saito, and M. Michikawa. 2009. Mechanism underly-
ing apolipoprotein E (ApoE) isoform-dependent lipid efflux from 
neural cells in culture. J. Neurosci. Res. 87: 2498–2508.
 61. Okoro, E. U., Y. Zhao, Z. Guo, L. Zhou, X. Lin, and H. Yang. 2012. 
Apolipoprotein E4 is deficient in inducing macrophage ABCA1 ex-
pression and stimulating the Sp1 signaling pathway. PLoS One. 7: 
e44430.
 62. Eckert, G. P., C. Reik, and W. E. Muller. 2013. Simvastatin alters 
membrane cholesterol distribution and beta-amyloid levels in 
brains of female APP751SL mice. Pharmazie. 68: 590–594.
 63. Phan, H. T., M. C. Vestergaard, K. Baek, N. Shimokawa, and M. 
Takagi. 2014. Localization of amyloid beta (Abeta1–42) protofibrils 
in membrane lateral compartments: effect of cholesterol and 7-ke-
tocholesterol. FEBS Lett. 588: 3483–3490.
 64. Kawarabayashi, T., M. Shoji, L. H. Younkin, L. Wen-Lang, D. W. 
Dickson, T. Murakami, E. Matsubara, K. Abe, K. H. Ashe, and S. G. 
Younkin. 2004. Dimeric amyloid beta protein rapidly accumulates 
in lipid rafts followed by apolipoprotein E and phosphorylated tau 
accumulation in the Tg2576 mouse model of Alzheimer’s disease. J. 
Neurosci. 24: 3801–3809.
 65. Whitehead, S. N., S. Gangaraju, A. Aylsworth, and S. T. Hou. 
2012. Membrane raft disruption results in neuritic retraction 
prior to neuronal death in cortical neurons. Biosci. Trends. 6: 
183–191.
 66. Sawamura, N., J. S. Gong, T. Y. Chang, K. Yanagisawa, and M. 
Michikawa. 2003. Promotion of tau phosphorylation by MAP kinase 
Erk1/2 is accompanied by reduced cholesterol level in detergent-

















Supplemental Material can be found at:
